US 11,717,573 B2
Methods and compositions for the treatment of cancer
Khosrow Rezvani, Vermillion, SD (US); and Grigoriy Sereda, Vermillion, SD (US)
Assigned to South Dakota Board of Regents, Pierre, SD (US)
Filed by South Dakota Board of Regents, Pierre, SD (US)
Filed on Sep. 28, 2020, as Appl. No. 17/35,293.
Claims priority of provisional application 62/907,569, filed on Sep. 28, 2019.
Prior Publication US 2021/0093726 A1, Apr. 1, 2021
Int. Cl. A61K 47/60 (2017.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); A61K 47/64 (2017.01); A61K 31/435 (2006.01)
CPC A61K 47/60 (2017.08) [A61K 9/5115 (2013.01); A61K 9/5161 (2013.01); A61K 9/5169 (2013.01); A61K 31/435 (2013.01); A61K 47/64 (2017.08); A61K 47/645 (2017.08); A61P 35/00 (2018.01)] 23 Claims
 
1. A composition comprising a veratridine (VTD) conjugate selected from the group consisting of polyglutamic acid-VTD (PLE-VTD) conjugate and polyethylene glycol/polyglutamic acid-VTD (PEG-PLE-VTD) conjugate.